-- BridgeBio Oncology Therapeutics (BBOT) said Wednesday its chief scientific officer Pedro Beltran has been appointed as chief executive officer of the company.
Idan Elmelech has also been appointed as chief operating officer, and Neil Kumar its executive chairman, BridgeBio said.
Elmelech previously served as senior vice president of strategy & business development, and Kumar played an integral role in the founding of BBOT as part of BridgeBio Pharma, the firm said.
Beltran succeeds Eli Wallace, who will transition into the a senior adviser role, the company said.
Price: $8.89, Change: $-0.57, Percent Change: -6.03%